Marshall Wace
LGND icon

Marshall Wace’s Ligand Pharmaceuticals LGND Stock Holding History

Marshall Wace’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,505
Closed -$1.5M – 3480
2026
Q1 		$1.5M Buy
+7,505
New +$1.48M ﹤0.01% 1939
2024
Q2 		– Sell
-6,636
Closed -$485K – 2763
2024
Q1 		$485K Buy
+6,636
New +$489K ﹤0.01% 1933
2023
Q4 		– Sell
-6,333
Closed -$379K – 2423
2023
Q3 		$379K Buy
+6,333
New +$417K ﹤0.01% 1802
2023
Q2 		– Sell
-27,583
Closed -$2.03M – 2735
2023
Q1 		$2.03M Sell
27,583
-65,280
-70% -$4.64M ﹤0.01% 1454
2022
Q4 		$6.2M Buy
92,863
+28,931
+45% +$1.88M 0.01% 1053
2022
Q3 		$3.43M Hold
63,932
– – 0.01% 1656
2022
Q2 		$3.56M Buy
+63,932
New +$3.63M 0.01% 1602
2021
Q4 		– Sell
-14,068
Closed -$1.22M – 4102
2021
Q3 		$1.22M Buy
+14,068
New +$1.09M 0.01% 1896
2021
Q1 		– Sell
-10,283
Closed -$638K – 2693
2020
Q4 		$638K Buy
+10,283
New +$586K ﹤0.01% 1377
2020
Q2 		– Sell
-8,140
Closed -$369K – 1785
2020
Q1 		$369K Buy
+8,140
New +$461K ﹤0.01% 1044
2019
Q3 		– Sell
-48,419
Closed -$3.45M – 1807
2019
Q2 		$3.45M Sell
48,419
-41,607
-46% -$3.06M 0.03% 605
2019
Q1 		$7.06M Sell
90,026
-157,694
-64% -$11.9M 0.07% 355
2018
Q4 		$21M Buy
247,720
+245,965
+14,015% +$26.2M 0.21% 107
2018
Q3 		$301K Sell
1,755
-7,321
-81% -$1.1M ﹤0.01% 1011
2018
Q2 		$1.17M Buy
+9,076
New +$1.01M 0.02% 491
2015
Q1 		– Sell
-152,490
Closed -$5.06M – 874
2014
Q4 		$5.06M Sell
152,490
-158,782
-51% -$5.17M 0.07% 310
2014
Q3 		$9.13M Buy
311,272
+305,841
+5,631% +$10.2M 0.13% 195
2014
Q2 		$211K Sell
5,431
-70,344
-93% -$2.85M ﹤0.01% 842
2014
Q1 		$3.18M Buy
+75,775
New +$3.16M 0.06% 286

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace's LGND Position: Q2 2026 in Review

Marshall Wace sold out of Ligand Pharmaceuticals (LGND) in Q2 2026, closing a stake of 7,505 shares — an estimated $1.5M sold.

Marshall Wace first reported a position in LGND in Q1 2014 and held it in 19 quarters. The position peaked at $21M in Q4 2018. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Marshall Wace reported no remaining Ligand Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Marshall Wace sold 7,505 Ligand Pharmaceuticals shares in Q2 2026, an estimated $1.5M.
  • Marshall Wace first reported a position in Ligand Pharmaceuticals in Q1 2014 and held it in 19 quarters.
  • Marshall Wace's Ligand Pharmaceuticals position peaked at $21M in Q4 2018.
  • 416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.